Guangzhou Fineimmune Biotechnology Co., Ltd.

This early-phase trial tests a new treatment called Super CAR-T for people with advanced liver cancer that has not responded to other therapies. The treatment uses a patient's own immune cells, modified to target a protein (GPC3) found on liver cancer cells. The main goals are to…

This early-phase trial tests a new treatment for people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line therapy. The treatment involves taking a patient's own immune cells, modifying them in the lab to better recognize and atta…